functional impairments according to ASS (American Shoulder and Elbow Surgeons Assessment) and CS (Constant Score), and a decrease in the need for NSAID use after 6 months. after the course of treatment.

Results: The dynamics of pain and functional disorders in the treatment of GLC and PRP did not differ. The pain decreased from 57.6 ± 17.8 to 30.2 ± 26.3 and 56.0 ± 14.6 to 31.8 ± 26.3 ($p = 0.768$), ASS from 54.7 ± 15.1 to 77.3 ± 22.5 and 54.8 ± 13.8 to 74.6 ± 22.4 ($p = 0.552$), CS from 47.8 ± 16.9 to 65.6 ± 19.3 and 59.2 ± 14.4 to 66.9 ± 17.4 ($p = 0.245$). In general, with the treatment of GLA and PRP, the dynamics of pain and functional disorders was significantly better in patients <45 years old than in patients ≥ 45 years old. So, pain according to VAS after 6 months. was 22.4 ± 26.3 and 35.5 ± 26.2 ($p = 0.022$), ASS 83.3 ± 20.9 and 72.1 ± 22.6 ($p = 0.017$), CS 76.2 ± 16 , 1 and 63.2 ± 18.2 ($p = 0.001$). There was no need to take NSAIDs in 82.4% and 65.2% of patients ($p = 0.103$). No serious adverse reactions have been reported with the treatment of GLC and PRP.

Conclusion: The efficacy of GLA and PRP in chronic shoulder pain caused by damage to the tendons to the muscles of the rotator of the shoulder does not differ. The clinical response to both drugs was significantly higher in those under 45 years of age.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.517

AB0715

THE PREVALENCE OF FIBROMYALGIA IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER AND THE RELATIONSHIP BETWEEN FATIGUE AND QUALITY OF LIFE

S. Ugurlu¹, T. Civi Karaaslan², Z. Toker Dincer¹, E. Tarakci². ¹Cerrahpasa Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey; ²Faculty of Health Sciences, Physiotherapy and Rehabilitation, Istanbul, Turkey

Background: Familial Mediterranean Fever (FMF) can cause various muscle diseases. Because it is a chronic auto inflammatory disease, painful trigger points may be encountered in the examination due to a decrease in the pain threshold (1-3).

Objectives: The aim of this study was to determine the prevalence of Fibromyalgia in patients with FMF; at the same time to identify the relationship between fatigue and quality of life.

Methods: Sixtyseven patients (38 female, 29 male) with FMF were enrolled in the study. They were diagnosed with FMF based on the Livneh diagnostic criteria (4). Fibromyalgia involvement of the patients was evaluated according to the Fibromyalgia Impact Questionnaire (FIQ). Patients with diagnose with other chronic disease were excluded. Fatigue Severity Scale (FSS) was used to evaluate fatigue. Quality of life was evaluated with Short Form-36 (SF-36).

Results: Respectively, the mean age, disease duration and body mass index were 34.46 ± 12.69 years, 12.66 ± 7.86 years and 24.96 ± 5.42 kg/m². In addition, 65% of the patients had no rheumatic disease in their family history. The mean of scores of FIQ was 38.66 ± 25.14 , the mean of FSS was 38.07 ± 17.56 , the mean of SF-36-PCS was 45.55 ± 10.54 and SF36-MCS was 30.93 ± 17.39 . Patients were categorized as mild (n=28), moderate (n=24) and severe (n=15) affected according to their FIQ score. The relationships of scores of FIQ, FSS and SF-36 were demonstrated Table 1.

Conclusion: Fibromyalgia symptoms can be seen in FMF. According to our results, it has been shown that patients with moderate and severe symptoms have increased fatigue levels and decreased quality of life. In the light of these results, we can say that also the fibromyalgia symptom of patients with FMF should be considered in the treatment.

REFERENCES:

- [1] Sari, Ismail; Birlik, Merih; Kasifoglu, Timucin. Familial Mediterranean fever: an updated review. European journal of rheumatology, 2014, 1.1: 21.
- [2] Alayli G, Durmus D, Ozkaya O, Sen HE, Genc G, Kuru O. Frequency of juvenile fibromyalgia syndrome in children with familial Mediterranean fever: effects on depression and quality of life. Clin Exp Rheumatol 2011; 29: S127-32.
- [3] Langevitz P, Buskila D, Finkelstein R, Zaks N, Neuman L, Sukenik S, et al. Fibromyalgia in familial Mediterranean fever. J Rheumatol 1994; 21: 1335-7.
- [4] Bashardoust, Bahman. Familial Mediterranean fever; diagnosis, treatment, and complications. Journal of nephropharmacology, 2015, 4.1: 5.

Table 1. The correlations of FIQ, FSS and SF-36 scores.

		FSS	SF-36 PCS	SF-36 MCS
FIQ-mild	mean±sd	23.78±14.88	53.34±7.01	40.98±13.73
	r	0.595**	-0.014	-0.551**
	p	0.001	0.944	0.002
FIQ-moderate	mean±sd	45.75±10.83	41.09±8.89	38.13±9.19
	r	0.053	-0.379	-0.145
	p	0.806	0.068	0.498
FIQ-severe	mean±sd	52.46±10.11	38.13±9.19	20.32±15.68
	r	0.622*	-0.548	-0.268
	p	0.013	0.035	0.333

-Pearson Correlation

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.1288

AB0716

FIBROMYALGIA SYNDROME SEVERITY ACCORDING TO AGE CATEGORIES: RESULTS FROM A NATIONAL REGISTER

M. Di Carlo¹, S. Farah², L. Bazzichi³, F. Atzeni⁴, M. Govoni⁵, G. Biasi⁶, M. Di Franco⁷, F. Mozzani⁸, E. Gremese⁹, L. Dagna¹⁰, A. Batticciotto¹¹, F. Fischetti¹², R. Giacomelli¹³, S. Guiducci¹⁴, G. Guggino¹⁵, M. Bentivegna¹⁶, R. Gerli¹⁷, C. Salvarani¹⁸, G. Bajocchi¹⁹, M. Ghini²⁰, F. Iannone²¹, V. Giorgi²², M. Cirillo⁴, S. Bonazza⁵, S. Barbagli⁶, C. Gioia⁷, N. G. Marino⁸, A. Capacci⁹, G. Cavalli¹⁰, A. Cappelli¹¹, F. Carubbi²³, F. Nacchi¹⁴, R. Ilenia¹⁷, M. Cutolo²⁴, L. Sinigaglia²⁵, P. Sarzi-Puttini²², F. Salaffi¹ on behalf of Italian Fibromyalgia Registry.

¹Università Politecnica delle Marche, Dipartimento di Scienze Cliniche e Molecolari - Rheumatology Clinic, Jesi, Italy; ²Università Politecnica delle Marche, Dipartimento di Scienze Cliniche e Molecolari - Rheumatology Clinic, Jesi, Italy; ³AOU Pisana, Rheumatology Unit, Pisa, Italy; ⁴Università di Messina, Department of Internal Medicine, Rheumatology Unit, Messina, Italy; ⁵University of Ferrara and Azienda Ospedaliera-Universitaria di Ferrara, Rheumatology, Department of Medical Sciences, Ferrara, Italy; ⁶University of Siena, Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, Siena, Italy; ⁷Sapienza University of Rome, Department of Internal Medicine and Medical Specialties, Rheumatology Unit, Roma, Italy; ⁸Azienda Ospedaliero-Universitaria di Parma, Department of Medicine, Internal Medicine and Rheumatology Unit, Parma, Italy; ⁹Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Reumatologia, Roma, Italy; ¹⁰IRCCS San Raffaele Scientific Institute, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Milano, Italy; ¹¹ASST Settelaghi, Ospedale Di Circolo - Fondazione Macchi, Rheumatology Unit, Internal Medicine Department, Varese, Italy; ¹²University of Trieste, Department of Medical Sciences, UCO Medicina Clinica (SSD Reumatologia), Trieste, Italy; ¹³University of Rome "Campus Biomedico" - School of Medicine, Division of Rheumatology and Clinical Immunology, Roma, Italy; ¹⁴University of Florence, Department of Experimental and Clinical Medicine, Divisions of Internal Medicine and Rheumatology AOUC, Firenze, Italy; ¹⁵University of Palermo, Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties, Palermo, Italy; ¹⁶ASP 7, Scicli Hospital, Integrated Reference Center of Rheumatology, Ragusa, Italy; ¹⁷University of Perugia, Rheumatology Unit, Department of Medicine, Perugia, Italy; ¹⁸University of Modena and Reggio Emilia, Azienda USL-IRCCS di Reggio Emilia, Rheumatology Unit, Reggio Emilia, Italy; ¹⁹S. Maria Hospital - USL, IRCCS Institute, Rheumatology Unit, Reggio Emilia, Italy; ²⁰Azienda USL di Modena, Rheumatology Unit, Modena, Italy; ²¹University of Bari, Rheumatology Unit, Department of Emergency and Organ Transplants, Bari, Italy; ²²ASST Fatebenefratelli-Sacco, Milan State University School of Medicine, Rheumatology Unit, Internal Medicine Department, Milano, Italy; ²³University of LAquila, Clinical Unit of Rheumatology, School of Medicine, LAquila, Italy; ²⁴University of Genoa, IRCCS San Martino, Department of Internal Medicine, Research Laboratory and Division of Clinical Rheumatology, Genova, Italy; ²⁵ASST Gaetano Pini-CTO, Division of Rheumatology, Milano, Italy

Background: Fibromyalgia syndrome (FM) is characterised by a complex symptom spectrum, dominated by the presence of chronic widespread pain, fatigue and unrefreshing sleep. FM affects between 2 and 3% of the general population. It is a condition that mainly involves middle-aged women, although it is increasingly being diagnosed in younger people. The severity of symptoms can vary greatly between individual patients, and is influenced by many factors (e.g. sex,

body mass index) [1]. To date, there is little information about changes in severity in accordance with patient age.

Objectives: The aim of this study was to investigate variations in symptom severity in FM patients according to age categories.

Methods: A cross-sectional study of adult FM patients diagnosed according to the American College of Rheumatology 2010/2011 criteria was performed. The case series was included from an Italian national registry [2]. Patients were grouped according to five age categories: 18-40 years, 41-50 years, 51-60 years, 61-70 years, over 71 years. Symptom severity was assessed through the revised Fibromyalgia Impact Questionnaire (FIQR) and domains, including FIQR physical function (items 1-9), FIQR health status (items 10-11), and FIQR symptoms (items 12-21). Between-group characteristics were analysed using one-way analysis of variance (ANOVA).

Results: This study included a total of 2889 patients, 403 aged 18-40 years, 756 aged 40-50 years, 1035 aged 50-60 years, 528 aged 60-70 years, and 167 over 70 years, respectively. The mean (standard deviation [SD]) score of the total FIQR was 52.68 (11.82). Total FIQR and individual domains all showed a normal distribution. Analysing the data by age category, there were statistically significant differences between the categories for the total FIQR ($p = 0.030$). The age categories with the highest disease severity were those above 71 years (FIQR 62.14, SD 22.45), and between 51-60 years (FIQR 60.31, SD 22.89) (Table 1). Significant differences between age categories were also found for the domains physical function ($p = 0.006$) and health status ($p = 0.012$), but not for the domain symptoms ($p = 0.164$).

Table 1. Mean values of FIQR total score and domains according to age categories.

FIQR and domains	18-40 years	41-50 years	51-60 years	61-70 years	≥71 years	p*
FIQR total, mean (SD)	57.90 (21.76)	59.25 (23.30)	60.31 (22.89)	57.13 (23.59)	62.14 (22.45)	0.030
FIQR physical function, mean (SD)	15.51 (7.56)	16.44 (7.77)	16.77 (7.51)	15.96 (7.82)	17.68 (7.26)	0.006
FIQR health status, mean (SD)	11.19 (5.85)	11.24 (5.99)	11.49 (5.93)	10.57 (6.11)	12.21 (5.97)	0.012
FIQR symptoms, mean (SD)	31.32 (10.48)	31.56 (11.32)	32.10 (11.01)	30.68 (11.47)	32.24 (11.34)	0.164

Abbreviations and legend. FIQR = revised Fibromyalgia Impact Questionnaire; SD = standard deviation; * = one-way analysis of variance (ANOVA).

Conclusion: Distinguishing the disease severity in FM patients according to age categories, a bimodal distribution emerges, with the disease severity being greatest in patients over 71 years and in the 51-60 years decade. The main differences in severity, according to what can be detected through the FIQR, are attributable to the domains physical function and health status, which show higher scores in the two classes with higher severity.

REFERENCES:

- [1] Sarzi-Puttini P et al., Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. *Nat Rev Rheumatol* 2020; 16: 645-660.
- [2] Salaffi F et al., The Italian Fibromyalgia Registry: a new way of using routine real-world data concerning patient-reported disease status in health-care research and clinical practice. *Clin Exp Rheumatol* 2020; Suppl 123: 65-71.

Acknowledgements: Società Italiana di Reumatologia (SIR) and Italian Ministry of Health

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.1507

AB0717

PREVALENCE OF MIGRAINE AND NEUROPATHIC PAIN AMONG PATIENTS WITH RHEUMATIC DISEASES

S. Miladi¹, M. Yasmine¹, A. Faza¹, S. Mariem¹, K. Ouenniche¹, L. Souebni¹, S. Kassab¹, S. Chekili¹, K. Ben Abdelghani¹, A. Laatar¹. ¹Mongi Slim Hospital, Rheumatology, Tunis, Tunisia

Background: Pain in rheumatic diseases (RD) is primarily due to mechanical or inflammatory mechanism, but neuropathic pain (NP) component is yet to be fully evaluated and described, with a particular attention to the distinction with nociceptive pain [1].

Objectives: The aim of our study was to assess the prevalence of migraine and neuropathic pain in patients with RD and to explore factors associated with NP.

Methods: Prospective study including patients with rheumatoid arthritis (RA) and spondylarthritis (SpA) were invited to complete a validated self-assessment

questionnaires. Sociodemographic data as well as disease related characteristics were recorded. Migraine was diagnosed according to the IHS migraine diagnostic criteria. NP was evaluated using DN4 (Douleur Neuropathique 4 Questions) and Pain DETECT questionnaire (PDQ). Neuropathic pain was retained in case of a total score of 4 or more at DN4-interview questionnaire or a score ≥19 with the PDQ.

Results: A total of 60 patients with RD were included (42 RA/18 SpA). Females outnumbered males (sex-ratio=1.7). The mean age was 51.3 ± 13.1 years [18-75] and the mean disease duration was 11.9 ± 5.6 [1-23] years. The prevalence of migraine was 15%. This latter was higher among women than men and among RA patients than SpA (18% vs 9%, 16.6% vs 11.2%) with no statistically significant correlation ($p=0.329$, 0.581 respectively). Parameters associated with a higher prevalence of migraine were an older age ($p=0.042$). However, there was no correlation between the presence of migraine and the type of the RD, disease duration or the level of anxiety ($p=0.059$, $p=0.459$ respectively). Chronic pain with neuropathic characteristics was found in 21.7% with the DECT score and 16.7% with DN4 questionnaire. NP was most prevalent among patients with comorbidities (28.5% vs 6%, $p=0.021$) and with higher body mass index ($p=0.01$). Prevalence was significantly higher in the RA group (19%) than in the SpA group (11%) without a statistically significant correlation ($p=0.45$). Similarly, NP was not associated with Salazopyrine intake ($p=0.9$).

Conclusion: We found a high prevalence of migraine and NP in our sample of patients with RD. It seems therefore important to check the presence of migraine or NP especially in patients with comorbidities and older ones.

REFERENCES:

- [1] Bailly F, Cantagrel A, Bertin P, et al. Part of pain labelled neuropathic in rheumatic disease might be rather nociplastic. *RMD Open*. 2020;6:e001326.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.2132

AB0718

ASSESSMENT OF SEXUAL DYSFUNCTION IN WOMEN AND MEN WITH FIBROMYALGIA SYNDROME

G. Mouna¹, J. Mahbouba¹, S. Zrou¹, I. Bejjia¹, M. Touzi¹, N. Bergaoui¹. ¹Rheumatology Department of CHU Fattouma Bourguiba, Rheumatology Department of CHU Fattouma Bourguiba, Monastir, Tunisia

Background: Fibromyalgia syndrome is a chronic musculoskeletal disease, which compromises physical, mental, and sexual health. Although concerns related to sexuality are commonly reported, the literature on sexual functioning in patient with fibromyalgia is limited to female patients.

Objectives: The aim of our study is to identify sexual dysfunction in women and men with fibromyalgia syndrome compared with patients with rheumatoid arthritis.

Methods: This is a cross-sectional comparative study: '34 patients with fibromyalgia syndrome compared to 100 patients with rheumatoid arthritis' conducted in the rheumatology department of CHU Fattouma Bourguiba de Monastir over a period from February to November 2017. We used the Female Sexual Function Index (FSFI) and the Sexual Health Inventory for Men (SHIM).

Results: Our sample comprised 34 patients with fibromyalgia (31 females and 3 males) and 100 patients with rheumatoid arthritis (58 females and 15 males). Sexual dysfunction was present in 100% of female patients with fibromyalgia syndrome compared to 60% of female patients with rheumatoid arthritis. Female patients with fibromyalgia syndrome had a decreased FSFI score: 10,3±8,74 versus 16,86±8,87 in the rheumatoid arthritis group with $p=0.001$. While among the male patients, we found no significant difference between the two groups.

Conclusion: Fibromyalgia syndrome had negative side effect on the sexual life of female patients. Recognition of this dysfunction and its inclusion in the multi-disciplinary management of fibromyalgia must be part of the treatment.

REFERENCES:

- [1] P. Romero-Alcalá et al., « Sexuality in male partners of women with fibromyalgia syndrome: A qualitative study », *PLoS One*, vol. 14, n° 11, nov. 2019, doi: 10.1371/journal.pone.0224990.
- [2] M. D. H. Besiroglu et M. D. M. Dursun, « The association between fibromyalgia and female sexual dysfunction: a systematic review and meta-analysis of observational studies », *Int J Impot Res*, vol. 31, n° 4, p. 288-297, juill. 2019, doi: 10.1038/s41443-018-0098-3.
- [3] T. M. Matarín Jiménez, C. Fernández-Sola, J. M. Hernández-Padilla, M. Correa Casado, L. H. Antequera Raynal, et J. Granero-Molina, « Perceptions about the sexuality of women with fibromyalgia syndrome: a phenomenological study », *J Adv Nurs*, vol. 73, n° 7, p. 1646-1656, juill. 2017, doi: 10.1111/jan.13262.
- [4] L. Bazzichiet al., « Fibromyalgia and sexual problems », *Reumatismo*, vol. 64, n° 4, p. 261-267, sept. 2012, doi: 10.4081/reumatismo.2012.261.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.3721